'Real Life' experience in a 'difficult to treat' patient population of non-Hodgkin lymphomas using the R-COMP regimen

Leuk Lymphoma. 2016 Dec;57(12):2919-2922. doi: 10.3109/10428194.2016.1169410. Epub 2016 Apr 11.

Authors

Affiliations

¹ a Hematology, Stem Cell Transplantation, Transfusion Medicine and Cellular Therapy Unit , University "Campus Bio-Medico" , Rome , Italy.
² b Department of Cellular Biotechnology and Hematology , University "Sapienza" of Rome , Italy.
³ c Cardiology Unit , University "Campus Bio-Medico" , Rome , Italy.
⁴ d Hematology Unit , S. Maria Goretti Hospital, AUSL Latina , Italy.

PMID: 27063923
DOI: 10.3109/10428194.2016.1169410

No abstract available

Publication types

Letter

MeSH terms

Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Cyclophosphamide / therapeutic use
Female
Humans
Lymphoma, Non-Hodgkin / drug therapy*
Lymphoma, Non-Hodgkin / mortality
Lymphoma, Non-Hodgkin / pathology
Male
Methotrexate / therapeutic use
Middle Aged
Prednisone / therapeutic use
Retrospective Studies
Rituximab / administration & dosage*
Survival Analysis
Treatment Outcome
Vincristine / therapeutic use

Substances

Rituximab
Vincristine
Cyclophosphamide
Prednisone
Methotrexate

Supplementary concepts

COMP protocol